Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• This invention relates to new uses of nitroxoline.
• a neurofibroma is a benign nerve-sheath tumour in the peripheral nervous system. In 90% of cases, they are found as stand-alone tumours, while the remainder are found in persons with neurofibromatosis type I (NF1), an autosomal- dominant genetically inherited disease. Neurofibromas can result in a range of symptoms from physical disfiguration and pain to cognitive disability and can transform into malignant tumours.
• NF1 neurofibromatosis type I
• Cutaneous (or derma!) neurofibromas originate in nerves in the skin and are typically associated with a single peripheral nerve. All neurofibromas are composed of a mixture of NF1 mutant Schwann ceils (SCs) with other nerve fiber elements, such as axons, fibroblasts, mastocytes, macrophages and endothelial cells.
• SCs Schwann ceils
• cNFs Three kinds are distinguished: 1) Discrete cNFs; sessile or pedunculated masses on the skin, which are fleshy and non-tender, and can vary in size, 2) Discrete sub-cNFs; lie below and look like bumps on the skin, which can sometimes be tender, and 3) Deep nodular neurofibromas; Involving tissues and organs underneath the dermis, but otherwise resembling cutaneous and subcutaneous neurofibromas.
• NF1 is caused by germline mutations of the NF1 tumor suppressor gene, which encodes the protein neurofibromin.
• Neurofibromin functions as a GTPase-activating (GAP) protein and inactivates the intracellular signal transduction protein Ras by converting the active GTP-bound form into its inactive GDP-bound form. This in turn leads to the downregulation of Ras activity. Loss of neurofibromin activity increases Ras activity, which In turn promotes the transcription of a number of genes required for cell growth and proliferation. Cutaneous neurofibromas appear in at least 99% of patients with NF1 and originate from Schwann cell lineage in the dermis. cNFs typically appear at puberty and tend to increase in number throughout life, so that they may reach thousands. Although of benign character, these tumors are disfiguring and often itching and painful, thus significantly affecting quality of life.
• GAP GTPase-activating
• Selumetinib is a selective inhibitor of mitogen-activated protein kinase kinase (MAPK kinase, MEK, MAP2K, and MAPKK) and has the systemic name 6-(4- bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5- carboxamide.
• Nitroxoline is used in humans as an antibiotic, it is not widely used but has been on the market since the 1960s. It is used in the treatment or prevention of biofilm infections, such as urinary tract infections. It is particularly effective at disrupting biofilms and it is the metal cation chelation property that is believed to be responsible for this action. Nitroxoline is metabolised in the liver to the corresponding sulphate and glucuronide metabolites. There is evidence that the metabolites both share the antimicrobial activity. It has also been used in anticancer settings via antiproliferative action. Nitroxoline has the systematic name 5-nitroquinolin-8-ol.
• the present invention is a composition comprising nitroxoline, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a cutaneous neurofibroma.
• nitroxoline is effective in treating and preventing a cutaneous neurofibroma.
• a first aspect of the invention is a composition comprising nitroxoline, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a cutaneous neurofibroma.
• a second aspect of the invention is use of nitroxoline, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment or prevention of a cutaneous neurofibroma.
• a third aspect of the invention provides a method of treating or preventing a cutaneous neurofibroma comprising administering the patient with a composition comprising nitroxoline or a pharmaceutically acceptable salt thereof.
• Figure 1 shows the preparation and passage of the floating sphere cultures for the in vitro study.
• Figure 2 shows the dose response effect of nitroxoline in the proliferation of Tom + NF1 +/- and Tom + NF1 -/- cells.
• Figure 3 shows the dose response effect of nitroxoline inducing cell death of Tom + NF1 +/- and Tom + NF1 -/- cells.
• Figure 4 shows fluorescent cNF tumour cells in the mouse skin using low power (5x) magnification.
• nitroxoline inhibits cell proliferation and increases apoptosis in tumor cells isolated from cutaneous neurofibromas derived from the NF1 -/- mouse model, and is therefore an effective treatment of a cutaneous neurofibroma.
• nitroxoline is used for the treatment or prevention of a cutaneous neurofibroma, wherein the subject has neurofibromatosis type I.
• treatment we refer to therapeutic (curative) treatment and/or amelioration treatment (improvement in a patient's condition), which includes reducing the size of a cutaneous neurofibroma or the number of cNFs.
• prevention or “preventing” as used herein, we refer to “prophylactic” treatment to prevent cNFs forming. This includes administering the compositions of the invention to a patient that has NF1 but a cutaneous neurofibroma has not developed or to a patient that has a cNF but the aim is to prevent more from developing.
• “Patient” and “subject” are used interchangeably and refer to the subject that is to be administered the nitroxoline.
• the subject is a human.
• the subject has neurofibromatosis type I.
• the subject is an adult.
• An “adult” is a person of 18 years of age or older.
• the subject is undergoing puberty, such as the subject is between 8 and 18 years old.
• nitroxoline is used for the treatment or prevention of a cutaneous neurofibroma, wherein the patient has had or is going to have surgery to remove some or all of the cutaneous neurofibroma. This may be particularly advantageous if the cutaneous neurofibroma is large and/or expands across tissue boundaries, so it is difficult to remove it all by surgery and/or a quick removal of at least some of it is desired/beneficial.
• a pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base.
• Pharmaceutically acceptable acids include both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulfonic, ethanesulfonic, salicylic, stearic, benzenesulfonic or p-toluenesulfonic acid.
• Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aryl amines or heterocyclic amines.
• the present invention is directed to a composition comprising nitroxoline, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a cutaneous neurofibroma.
• the present invention is directed to a composition comprising nitroxoline, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a cutaneous neurofibroma, wherein nitroxoline is the only active agent in the composition.
• nitroxoline is the only active agent in the composition.
• the composition further comprises a second active agent for treating cutaneous neurofibroma, preferably wherein the second active agent is selumetinib, or a pharmaceutically acceptable salt thereof.
• the present invention is directed to a composition comprising nitroxoline, or a pharmaceutically acceptable salt thereof, for use in combination with a second composition comprising selumetinib, or a pharmaceutically acceptable salt thereof, wherein the two compositions are administered to the subject simultaneously, separately or sequentially.
• “separate” administration means that the drugs are administered as part of the same overall dosage regimen (which could comprise a number of days), but preferably on the same day.
• “simultaneously” means that the drugs are to be taken together or formulated as a single composition.
• “sequentially” means that the drugs are administered at about the same time, and preferably within about 1 hour of each other.
• the drugs are administered simultaneously i.e. taken together or formulated as a single composition. Most preferably, they are formulated as a single composition.
• the compositions of the invention may contain a pharmaceutically acceptable carrier.
• pharmaceutically acceptable carrier is meant any diluent or excipient, such as fillers or binders, that is compatible with the other ingredients of the composition, and which is not deleterious to the recipient.
• the pharmaceutically acceptable carrier can be selected on the basis of the desired route of administration, in accordance with standard pharmaceutical practices.
• the composition may be administered in a variety of dosage forms.
• the composition may be formulated in a format suitable for oral, rectal, parenteral, intranasal or transdermal administration or administration by inhalation or by suppository.
• the composition may be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
• the composition is formulated such that it is suitable for oral administration, for example tablets and capsules.
• Tablets and capsules may be prepared with binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, celluloses or polyvinylpyrrolidone; fillers, such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine; lubricants, such as magnesium stearate, talc, polyethylene glycol, or silica; and surfactants, such as sodium lauryl sulfate.
• binding agents for example, syrup, acacia, gelatin, sorbitol, tragacanth, celluloses or polyvinylpyrrolidone
• fillers such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine
• lubricants such as magnesium stearate, talc, polyethylene glycol, or silica
• surfactants such as sodium lauryl sulfate.
• Liquid compositions may contain conventional additives such as suspending agents, for example sorbitol syrup, methyl cellulose, sugar syrup, gelatin, carboxymethyl-cellulose, or edible fats; emulsifying agents and surfactants such as lecithin, or acacia; vegetable oils such as almond oil, coconut oil, cod liver oil, or peanut oil; preservatives such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
• suspending agents for example sorbitol syrup, methyl cellulose, sugar syrup, gelatin, carboxymethyl-cellulose, or edible fats
• emulsifying agents and surfactants such as lecithin, or acacia
• vegetable oils such as almond oil, coconut oil, cod liver oil, or peanut oil
• preservatives such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
• BHA butylated hydroxyanisole
• BHT buty
• the composition may also be administered by inhalation.
• inhaled medications are their direct delivery to the area of rich blood supply in comparison to many medications taken by oral route. Thus, the absorption is very rapid as the alveoli have an enormous surface area and rich blood supply and first pass metabolism is bypassed.
• the present invention also provides an inhalation device containing the composition of the present invention. Typically said device is a metered dose inhaler (MDI), which contains a pharmaceutically acceptable chemical propellant to push the medication out of the inhaler.
• MDI metered dose inhaler
• the composition may also be administered by intranasal administration.
• the nasal cavity’s highly permeable tissue is very receptive to medication and absorbs it quickly and efficiently. Nasal drug delivery is less painful and invasive than injections, generating less anxiety among patients.
• the present invention also provides an intranasal device containing the composition according to the present invention.
• the composition may also be administered by transdermal administration.
• transdermal and transmucosal patches, creams, ointments, jellies, solutions or suspensions, or micro needling may be employed.
• the present invention therefore also provides a transdermal patch containing the composition.
• the composition may also be administered by sublingual administration.
• the present invention therefore also provides a sub-lingual tablet comprising the composition.
• compositions may also be formulated with an agent which reduces degradation of the substance by processes other than the normal metabolism of the patient, such as anti-bacterial agents, or inhibitors of protease enzymes which might be the present in the patient or in commensural or parasite organisms living on or within the patient, and which are capable of degrading the compound.
• Liquid dispersions for oral administration may be syrups, emulsions and suspensions. Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
• the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g.
• compositions for injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
• the composition is administered in an effective amount to treat or prevent a cutaneous neurofibroma.
• An effective dose will be apparent to one skilled in the art, and is dependent on a number of factors including age, sex, weigh, which the medical practitioner will be capable of determining.
• the composition comprises 30 mg to 600 mg, preferably 50 mg to 500 mg, more preferably 100 mg to 400 mg, yet more preferably 150 mg to 350 mg, most preferably 200 mg to 300 mg nitroxoline.
• the composition may be administered once a day, twice a day, three times a day or four times a day. In an embodiment of the invention, the composition is administered at least once a day. Preferably it is administered as a single daily dose. Preferably the single daily dose is 90 mg to 1800 mg, preferably 150 mg to 1500 mg, more preferably 300 mg to 1200 mg, yet more preferably 450 mg to 1050 mg, most preferably 600 mg to 900 mg of nitroxoline. In an embodiment of the invention, the composition is administered twice daily.
• each dose is 45 mg to 900 mg, preferably 75 mg to 750 mg, more preferably 150 mg to 600 mg, yet more preferably 225 mg to 525 mg, most preferably 300 mg to 450 mg of nitroxoline.
• the composition is administered three times daily.
• each dose is 30 mg to 600 mg, preferably 50 mg to 500 mg, more preferably 100 mg to 400 mg, yet more preferably 150 mg to 350 mg, most preferably 200 mg to 300 mg of nitroxoline.
• the composition is administered four times daily.
• each dose is 15 mg to 500 mg, preferably 50 mg to 400 mg, more preferably 100 mg to 300 mg, yet more preferably 125 mg to 225 mg, most preferably 150 mg to 200 mg of nitroxoline.
• the dosage regime is such that the total daily dosage of nitroxoline does not exceed 1500 mg.
• the effective dose of nitroxoline results in a concentration of 1 to 75 ⁇ M, preferably 5 to 50 ⁇ M, more preferably 10 to 40 ⁇ M in cells.
• the composition comprising nitroxoline and the second composition comprising the second active agent, preferably selumetinib are a single daily dose.
• the two compositions are administered simultaneously i.e.
• compositions may also be administered sequentially i.e. at about the same time, and preferably within about 1 hour of each other.
• the compositions comprising selumetinib comprise between 1 mg and 75 mg of selumetinib, preferably between 5 mg to 50 mg of selumetinib, more preferably between 10 mg to 35 mg of selumetinib, most preferably between 15 mg to 30 mg of selumetinib.
• the effective dose of selumetinib administered to the subject is between 1 mg/m 2 and 75 mg/m 2 of selumetinib, preferably between 5 mg/m 2 to 50 mg/m 2 of selumetinib, more preferably between 10 mg/m 2 to 35 mg/m 2 of selumetinib, most preferably between 15 mg/m 2 to 30 mg/m 2 of selumetinib.
• the composition comprising nitroxoline is used in a chronic dosage regime i.e. chronic, long-term treatment.
• the regime lasts for at least one month, suitably at least two months, such as at least three months.
• the present invention also relates to a kit comprising: (i) at least one dose of nitroxoline, or a pharmaceutically acceptable salt thereof; and optionally (ii) at least one dose of selumetinib, or a pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use in the treatment or prevention of a cutaneous neurofibroma.
• the present invention also relates to use of nitroxoline, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment or prevention of a cutaneous neurofibroma.
• This embodiment of the invention may have any of the preferred features described above.
• the present invention also relates to a method of treating or preventing a cutaneous neurofibroma comprising administering the patient with a composition comprising nitroxoline or a pharmaceutically acceptable salt thereof.
• This embodiment of the invention may have any of the preferred features described above.
• the method of administration may be according to any of the routes described above.
• the present invention also embraces prodrugs which react in vivo to give a compound of the present invention.
• the assay was performed ex vivo using non-adherent cells in which Tomato expressing Nf1-/- and Nf1+/- stem-like cells from skin can be amplified, and their properties further characterized. While in this experimental condition, all differentiated cells die rapidly (24h), glial-stem like cells at the origin of cNFs survive, proliferate and form neurospheres (multicellular compact structures) that can be propagated for long periods, hence preserving their in vivo properties. In this system, Nf1-/- cells express high levels of p-ERK (as expected due to the permanent activation of the RAS pathway), proliferate much faster compared to controls and preserve the capacity to reform spheres after dissociation and re-plating.
• p-ERK as expected due to the permanent activation of the RAS pathway
• mice skin from young mutant (NF1-/- ) and control (NF1+/-) mice was dissected, dissociated and cell suspension incubated in the non-adherent condition with the presence of two mitogens, FGF and EGF. In such conditions only stem-like cells survive, proliferate and form compact multicellular floating structures called neurospheres. Since, in addition to the Tom+ glial stem-like cells, skin contains various other types of stem cells (Tom-), the neurospheres are composed of the intermingled Tom+ and Tom- cells.
• Tom- stem cells
• neurospheres While in the mutant condition, neurospheres contain Tom+, Nf1-/- and Tom-, Nf1+/+ cells, in the Nf1+/- control condition neurospheres are composed of Tom+, Nf1+/- and Tom-, Nf1+/+ cells.
• this study we have analysed the drug effect in Tom + from NF1 -/- and NfF1 +/- mice.
• Experimental Design Cell preparation, clonal expansion and drug treatment In the present study, floating sphere culture of Nf1+/- (Prss56Cre, R26Tom, Nf1flox/+) and Nf1-/- (Prss56Cre, R26Tom, Nf1flox/flox) glial cells isolated from newborn mouse skin were used.
• Nf1+/- and Nf1-/- spheres were amplified until passage 3 (1 passage corresponds to 7 days of culture).
• P0 10 days
• cells were split into 4 identical batches (clones 1-4), and were amplified to P3 ( Figure 1).
• spheres from each clone were dissociated and cells transferred into two 12 well plates. 6 different concentrations (100 ⁇ m, 33 ⁇ m, 10 ⁇ m, 3 ⁇ m, 1 ⁇ m and 0 ⁇ m) of drug were added and cells were incubated for 72h.
• Cell Death At 72h of culture, cells were labelled for quantification of cell death using DAPI (4 ⁇ ,6- diamidino-2-phenylindole).
• Nf1-KO mice This study uses the same mouse model that was used for in vitro testing, the Prss56Cre/+, R26tdTom/+, NF1fl/fl mouse (Radomska et a., 2019). This study is a standard experimental design in the field with endpoints being terminal and not longitudinal throughout study. Prss56Cre/+, R26tdTom/+, NF1fl/fl herein referred to as Nf1-KO mice develop cNFs after one year of age.
• mice fighting occurs at an earlier age after skin injury induced by mice fighting, which is normal mouse behaviour.
• mice at least five six-week old Nf1-KO male mice were placed in a cage together, once the mice had sustained a level of skin injury via fighting they were removed from the cage and monitored.
• the mice that had sustained fighting injuries developed several cNFs.
• a fluorescent reporter gene is turned on in cells that have Nf1 deleted, cNF development could be monitored via fluorescent imaging of the skin using an epifluorescent microscope (Leica MZ75). After 1-2 months mice that had established, mature cNFs were then enrolled into a drug treatment study.
• mice were either treated with vehicle via oral gavage (20% DMSO in 80% corn oil) or with 120mg/kg nitroxoline via oral gavage once a day (5 days on, 2 days off) for one month.
• Ex vivo analysis Mice were sacrificed after one month of treatment. Epifluorescent imaging was used to guide dissection of skin areas that had cNFs present. cNFs were dissected by punch biopsy (5mm) and fixed in 4% PFA overnight, then cryoprotected in 30% sucrose. Finally, samples were embedded in gelatin/sucrose (15%/7.5%). cNFs were cryosectioned (14um) and fluorescent Tom+ cells were imaged using a fluorescent microscope (Leica M165FC).

Landscapes

• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=76838879

Family Applications (1)

Country Status (12)

Cited By (2)

Citations (1)

• 2021
  • 2021-06-09 GB GBGB2108224.3A patent/GB202108224D0/en not_active Ceased
• 2022
  • 2022-06-09 BR BR112023025789A patent/BR112023025789A2/pt unknown
  • 2022-06-09 KR KR1020247000745A patent/KR20240024175A/ko active Pending
  • 2022-06-09 MX MX2023014530A patent/MX2023014530A/es unknown
  • 2022-06-09 AU AU2022290019A patent/AU2022290019A1/en active Pending
  • 2022-06-09 US US18/567,829 patent/US20240261276A1/en active Pending
  • 2022-06-09 EP EP22732622.0A patent/EP4351576A1/en active Pending
  • 2022-06-09 WO PCT/GB2022/051442 patent/WO2022258972A1/en not_active Ceased
  • 2022-06-09 CA CA3221964A patent/CA3221964A1/en active Pending
  • 2022-06-09 CN CN202280040639.5A patent/CN117769419A/zh active Pending
  • 2022-06-09 IL IL309177A patent/IL309177A/en unknown
  • 2022-06-09 JP JP2023574531A patent/JP2024520690A/ja active Pending

Patent Citations (1)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events